Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1977 1
1978 1
1980 1
1982 3
1983 1
1984 4
1985 5
1986 6
1987 8
1988 16
1989 4
1990 3
1991 1
1992 5
1993 5
1994 6
1995 5
1996 1
1997 1
1998 1
1999 8
2000 9
2001 10
2002 11
2003 17
2004 11
2005 16
2006 11
2007 23
2008 17
2009 16
2010 24
2011 13
2012 13
2013 27
2014 42
2015 49
2016 49
2017 66
2018 84
2019 89
2020 115
2021 122
2022 117
2023 116
2024 71

Text availability

Article attribute

Article type

Publication date

Search Results

1,064 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Eivazi-Arvanagh
Page 1
Behcet's disease.
Davatchi F. Davatchi F. Int J Rheum Dis. 2014 May;17(4):355-7. doi: 10.1111/1756-185X.12378. Epub 2014 Apr 25. Int J Rheum Dis. 2014. PMID: 24762121 No abstract available.
A brief history of NEDA.
Giovannoni G, Bermel R, Phillips T, Rudick R. Giovannoni G, et al. Mult Scler Relat Disord. 2018 Feb;20:228-230. doi: 10.1016/j.msard.2017.07.011. Epub 2017 Jul 13. Mult Scler Relat Disord. 2018. PMID: 29579628 No abstract available.
Are we in need of NEDA?
Freedman MS. Freedman MS. Mult Scler. 2016 Jan;22(1):5-6. doi: 10.1177/1352458515617249. Epub 2015 Nov 9. Mult Scler. 2016. PMID: 26552731 No abstract available.
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, Shubin R, Wray S, Weiss MS, Bosco JA, Power SA, Mok K, Inglese M. Fox E, et al. Mult Scler. 2021 Mar;27(3):420-429. doi: 10.1177/1352458520918375. Epub 2020 Apr 30. Mult Scler. 2021. PMID: 32351164 Free PMC article. Clinical Trial.
Overall, 74% of patients had no evidence of disease activity (NEDA). CONCLUSION: Ublituximab was safely infused as rapid as 1 hour, producing robust B-cell depletion and profound reductions in magnetic resonance imaging (MRI) activity and relapses....
Overall, 74% of patients had no evidence of disease activity (NEDA). CONCLUSION: Ublituximab was safely infused as rapid as 1 hour, p …
No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].
Newsome SD, Binns C, Kaunzner UW, Morgan S, Halper J. Newsome SD, et al. Neurol Ther. 2023 Dec;12(6):1909-1935. doi: 10.1007/s40120-023-00549-7. Epub 2023 Oct 11. Neurol Ther. 2023. PMID: 37819598 Free PMC article. Review.
We identify current challenges to the use of NEDA in clinical practice and detail the proposed amendments, such as the inclusion of alternative outcomes and biomarkers, to broaden the clinical information captured by NEDA. ...One such outcome is the set of criteria …
We identify current challenges to the use of NEDA in clinical practice and detail the proposed amendments, such as the inclusion of a …
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T. Kappos L, et al. JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405. JAMA Neurol. 2021. PMID: 33779698 Free PMC article. Clinical Trial.
Exploratory end points included the percentage change in brain volume and no evidence of disease activity (NEDA-3 and NEDA-4) status. RESULTS: For 1133 patients (567 receiving ponesimod and 566 receiving teriflunomide; median [range], 37.0 [18-55] years; 735 women [ …
Exploratory end points included the percentage change in brain volume and no evidence of disease activity (NEDA-3 and NEDA-4) …
NEDA treatment target? No evident disease activity as an actionable outcome in practice.
Parks NE, Flanagan EP, Lucchinetti CF, Wingerchuk DM. Parks NE, et al. J Neurol Sci. 2017 Dec 15;383:31-34. doi: 10.1016/j.jns.2017.10.015. Epub 2017 Oct 13. J Neurol Sci. 2017. PMID: 29246616 Review.
NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable tr …
NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA rema …
Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population.
Simonsen CS, Flemmen HØ, Broch L, Brekke K, Brunborg C, Berg-Hansen P, Celius EG. Simonsen CS, et al. Front Neurol. 2022 Nov 14;13:1034056. doi: 10.3389/fneur.2022.1034056. eCollection 2022. Front Neurol. 2022. PMID: 36452173 Free PMC article.

PwMS who achieved NEDA at year one had a mean time to EDSS 6 of 33.8 (95% CI 30.9-36.8) years vs. 30.8 (95% CI 25.0-36.6) years in pwMS who did not achieve NEDA, p < 0.001. When rebaselining NEDA 1 year after diagnosis, 52.2% achieved NEDA in the 1s

…
PwMS who achieved NEDA at year one had a mean time to EDSS 6 of 33.8 (95% CI 30.9-36.8) years vs. 30.8 (95% CI 25.0-36.6) years in pw …
[Alemtuzumab therapy 2017].
Biernacki T , Bencsik K , Sandi D , Vécsei L . Biernacki T , et al. Ideggyogy Sz. 2017 Nov 30;70(11-12):371-380. doi: 10.18071/isz.70.0371. Ideggyogy Sz. 2017. PMID: 29870645 Free article. Review. Hungarian.
A patient's disease is considered inactive, if it fulfills the criteriae set in the "no evidence of disease activity-3" (NEDA-3) concept, meaning that no progression can be seen on the MRI scans, the patient is relapse free and there is no worsening on any disability scale …
A patient's disease is considered inactive, if it fulfills the criteriae set in the "no evidence of disease activity-3" (NEDA-3) conc …
Current concepts in multiple sclerosis therapy.
Sedal L, Winkel A, Laing J, Law LY, McDonald E. Sedal L, et al. Degener Neurol Neuromuscul Dis. 2017 Sep 28;7:109-125. doi: 10.2147/DNND.S109251. eCollection 2017. Degener Neurol Neuromuscul Dis. 2017. PMID: 30050382 Free PMC article. Review.
1,064 results